(Q33988105)

30 July 2017

1 reference

title

Long-term effects of interferon therapy on histology and development of hepatocellular carcinoma in hepatitis C. (English)

1 reference

30 July 2017

main subject

hepatocellular carcinoma

1 reference

Omata M

1

1 reference

30 July 2017

Shiratori Y

series ordinal

2

1 reference

30 July 2017

publication date

1 May 2000

1 reference

Journal of Gastroenterology and Hepatology

30 July 2017

published in

1 reference

30 July 2017

volume

15 Suppl

1 reference

30 July 2017

page(s)

E134-40

1 reference

Long-term mortality after transfusion-associated non-A, non-B hepatitis. The National Heart, Lung, and Blood Institute Study Group

30 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2000.02115.X

Clinical outcomes after transfusion-associated hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2000.02115.X

Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2000.02115.X

The treatment of chronic viral hepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2000.02115.X

Significance of serum hepatitis C virus RNA levels in chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2000.02115.X

Predictors of the efficacy of interferon therapy in chronic hepatitis C virus infection. Tokyo-Chiba Hepatitis Research Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2000.02115.X

Therapy of hepatitis C: overview

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2000.02115.X

Persistent hepatitis C viremia predicts late relapse after sustained response to interferon-alpha in chronic hepatitis C. TriVeneto Viral Hepatitis Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2000.02115.X

Two-year biochemical, virological, and histological follow-up in patients with chronic hepatitis C responding in a sustained fashion to interferon alfa-2b treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2000.02115.X

Biochemical and virological outcome of patients with chronic hepatitis C treated with interferon alfa-2b for 6 or 12 months: a 4-year follow-up of 211 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2000.02115.X

Relationship between biochemical, virological, and histological response during interferon treatment of chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2000.02115.X

Classification of chronic viral hepatitis: a need for reassessment

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2000.02115.X

Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2000.02115.X

Classification of chronic hepatitis: diagnosis, grading and staging

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2000.02115.X

An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2000.02115.X

Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2000.02115.X

Slow progression rate of fibrosis in hepatitis C virus patients with persistently normal alanine transaminase activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2000.02115.X

Time course of histological changes in patients with a sustained biochemical and virological response to interferon-alpha therapy for chronic hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2000.02115.X

Long-term histological outcome in patients with chronic hepatitis C treated repeatedly with interferon alpha-2b without sustained response

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2000.02115.X

Modeling the impact of interferon alfa treatment on liver fibrosis progression in chronic hepatitis C: a dynamic view. The Multivirc Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2000.02115.X

10-Year follow-up after interferon-alpha therapy for chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2000.02115.X

Long-term histologic improvement and loss of detectable intrahepatic HCV RNA in patients with chronic hepatitis C and sustained response to interferon-alpha therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2000.02115.X

Incidence of hepatocellular carcinoma in chronic hepatitis B and C: a prospective study of 251 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2000.02115.X

Randomised trial of effects of interferon-alpha on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2000.02115.X

Alpha interferon treatment may prevent hepatocellular carcinoma in HCV-related liver cirrhosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2000.02115.X

Prognosis of chronic hepatitis C: results of a large, prospective cohort study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2000.02115.X

Determinants of outcome of compensated hepatitis C virus-related cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2000.02115.X

Risk factors and the effect of interferon therapy in the development of hepatocellular carcinoma: a multivariate analysis in 343 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2000.02115.X

Risk factors for hepatocellular carcinoma and its incidence after interferon treatment in patients with chronic hepatitis C. Osaka Liver Disease Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2000.02115.X

Relation of interferon therapy and hepatocellular carcinoma in patients with chronic hepatitis C. Osaka Hepatocellular Carcinoma Prevention Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2000.02115.X

Effect of interferon therapy on hepatocellular carcinogenesis in patients with chronic hepatitis type C: A long-term observation study of 1,643 patients using statistical bias correction with proportional hazard analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2000.02115.X

Varying incidence of cirrhosis and hepatocellular carcinoma in patients with chronic hepatitis C responding differently to interferon therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2000.02115.X

Interferon therapy reduces the risk for hepatocellular carcinoma: national surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. IHIT Study Group. Inhibition of Hepatocarcinogenesis by Interferon Therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2000.02115.X

Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C: Effects of dose and duration

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2000.02115.X

Intraobserver and interobserver variations in liver biopsy interpretation in patients with chronic hepatitis C

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2000.02115.X

10.1046/J.1440-1746.2000.02115.X

21 January 2018

Identifiers

DOI

1 reference

30 July 2017

1 reference